A New Alzheimer’s Drug Offers More Questions Than Answers

“It puts us in a bad place,” agreed Dr. Karina Bishop, a geriatrician at the University of Nebraska Medical Center. Ethically, she added,...

“It puts us in a bad place,” agreed Dr. Karina Bishop, a geriatrician at the University of Nebraska Medical Center. Ethically, she added, “if this drug was available right now, I would not feel able to prescribe it.”

Even as individual doctors grapple with advising patients, hospitals and health systems are devising protocols for when Aduhelm becomes available, probably within weeks.

At the Mayo Clinic, said Dr. Ronald Petersen, a neurologist who directs the Alzheimer’s Disease Research Center there, “we’re going to stick pretty close to the inclusion and exclusion criteria used in the trial.”

That means only patients with mild cognitive impairment or early Alzheimer’s disease would qualify, after an M.R.I. to rule out certain conditions and risks, and a P.E.T. scan or lumbar puncture to confirm the presence of amyloid. The Mayo protocols, like the clinical trials, would exclude people taking blood thinners like Warfarin or Eliquis.

“It’s not like you come in and say, ‘I’m a little forgetful,’ and we say, ‘Here’s this drug,’” said Dr. Petersen. But not every provider, he acknowledged, will employ such safeguards.

Dr. Eric Widera, a geriatrician at the University of California, San Francisco, expressed a similar concern: “If doctors were extremely cautious and limited this drug to the very specific population included in the study, with very careful monitoring, it would be the first time in medicine that was ever done.”

He pointed out another consequence of federal approval: a rift between some doctors and the Alzheimer’s Association, the national advocacy group, which this spring mounted a campaign it called More Time. Intended to demonstrate public support for approval of aducanumab, the effort included newspaper ads and social media posts.

Source Link



Africa,846,Americas,4187,Art & Culture,15179,Arts,6592,Arts & Design,1734,Asia,3374,Automobile,478,Baseball,671,Basketball,562,Books,3988,Business,5457,Celebrity,2633,Cricket,648,Crime,158,Cryptocurrency,1703,Dance,582,Defense,836,Diplomatic Relations,2496,Economy,1197,Editorial,260,Education,1302,Elections,308,Energy & Environment,3088,Entertainment,22968,Environment,3699,Europe,4319,Faith & Religion,235,Family & Life,817,Fashion & Style,3371,Finance,20416,Food & Drink,3849,Football,1125,Games,97,Gossip,10289,Health & Fitness,4196,Health Care,943,Hockey,234,Home & Garden,920,Humour,994,Latin America,49,Lifestyle,17465,Media,527,Middle East,1586,Movies,1815,Music,2739,Opinion,3308,Other,12226,Other Sports,5165,Political News,11324,Political Protests,2324,Politics,18008,Real Estate,1968,Relationship,106,Retail,3116,Science,2723,Science & Tech,10317,Soccer,274,Space & Cosmos,361,Sports,12532,Technology,3534,Tennis,608,Theater,1753,Transportation,313,Travel,2635,TV,3773,US,755,US Sports,1481,Video News,3531,War & Conflict,1069,Weird News,998,World,16947,
Newsrust - US Top News: A New Alzheimer’s Drug Offers More Questions Than Answers
A New Alzheimer’s Drug Offers More Questions Than Answers
Newsrust - US Top News
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS PREMIUM CONTENT IS LOCKED STEP 1: Share to a social network STEP 2: Click the link on your social network Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy Table of Content